Alirocumab safe in patients with diabetes mellitus PROFICIO analysis shows consistent LDL lowering with evolocumab International Atherosclerosis Society and FH Foundation join forces to improve FH management ESC 2018: FOURIER analysis: Greater benefit with evolocumab in metabolic syndrome patients ESC 2018: FOURIER: Evolocumab shows similar benefit in men, women and the elderly ESC 2018: Real-world data vindicate ESC/EAS guidance for PCSK9 inhibitors Two more analyses show efficacy of alirocumab in diabetes OSLER: sustained benefit with evolocumab in statin intolerant patients

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

News from ESC Congress, Munich
Germany, 25-29 August 2018

FOURIER: Evolocumab shows benefit in metabolic syndrome

News from ISA 2018

News from ODYSSEY Outcomes: Lipoprotein(a) is a risk marker

News from ACC 2018

Most viewed

Editorial Board International Atherosclerosis Society and FH Foundation join forces to improve FH management Alirocumab safe in patients with diabetes mellitus Trials PROFICIO analysis shows consistent LDL lowering with evolocumab Videos Two more analyses show efficacy of alirocumab in diabetes Updated Canadian Consensus on statin intolerance FH and PCSK9: Perspective from Japan PCSK9 Monoclonal Antibody Therapy in Patients with Diabetes: Where We Are and Future Needs

Most viewed

Editorial Board

Lipoprotein(a) – does it matter when LDL cholesterol is low?

Lipoprotein(a) is now recognised as an independent risk factor for cardiovascualr disease.

But is it also relevant to consider lipoprotein(a) when LDL cholesterol is low?

Prof. Anthony S Wierzbicki, Guy’s and St Thomas’ Hospitals, London, UK discusses the evidence.

Read the report

Hot Topics

Guidance needed on LDL lowering in very high-risk patients

Do high and very high-risk patients at guideline-recommended goal gain more benefit from further lowering LDL cholesterol levels? PCSK9 Forum Editor Professor John Chapman (UPMC-Sorbonne, Director Emeritus, INSERM, Paris, France), discusses.

Read the report

Video: Impetus to change LDL-C goal from FOURIER
Watch the video

From the Editors

The lipoprotein(a) – LDL cholesterol conundrum

Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses issues related to lowering elevated lipoprotein(a): is it beneficial when LDL cholesterol is low?

Read the article

Lowering lipoprotein(a) when LDL-C is very low

Watch the video

Lowering lipoprotein(a) for clinical benefit

Watch the video

How much lipoprotein(a) lowering for CV benefit?

Read the report